Cardiovascular Bioengineering 2021 Symposium

心血管生物工程2021研讨会

• 批准号: 10237721
• 负责人: Timothy J. Kamp
• 金额: $ 1万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10237721
• 关键词: Americas; Anniversary; Area; Australia; Award; Biomedical Engineering; Budgets; COVID-19; Cardiac; Cardiac development; Cardiovascular system; Cell Therapy; Cells; Cellular biology; China; Collaborations; Europe; Fostering; Genes; Germany; Goals; Grant; Heart Diseases; Heart failure; Individual; Innovative Therapy; International; Japan; Learning; Life; MicroRNAs; Minority; Mitochondria; Molecular; Myocardium; National Heart, Lung, and Blood Institute; New Zealand; Paper; Pluripotent Stem Cells; Positioning Attribute; Postdoctoral Fellow; Request for Proposals; Research; Research Personnel; Schedule; Science; Scientist; Tissue Engineering; Translations; Travel; Tungsten; Underrepresented Minority; Universities; Videotape; Work; career; cost; design; exosome; experience; graduate student; induced pluripotent stem cell; lectures; meetings; next generation; outreach; programs; recruit; stem cell biology; stem cells; symposium

PROJECT SUMMARY/ABSTRACT This is a new application for the Cardiovascular Bioengineering 2021 (CVBE 2021) Symposium to be held on the campus of the University of Göttingen, Germany. This will be the 6th Anniversary of the Symposium. The uniqueness of the proposed CVBE symposium lies in its combination of top researchers in cardiovascular bioengineering with underrepresented trainees in the field. Trainees are graduate students and post-doctoral fellows in the cardiovascular sciences and biomedical engineering. The symposium will provide a forum for trainees and junior investigators to present their work in the areas of gene editing, induced pluripotent stem cells, and cardiac stem cells in the context of heart failure as well general topics in cardiovascular bioengineering. This conference grew out of initiatives from the NHLBI progenitor cell biology consortium (PCBC) and brought together initially PCBC cardiovascular researchers and their trainees as well as invited speakers. In 2016, as the PCBC was replaced by NHLBI progenitor cell translation consortium (PCTC), the meeting grew to a public symposium to broadly engage both PCBC investigators as well as others in in cardiovascular bioengineering. Proceedings and position papers have emerged from the meeting over the years,1-5 and it is now recognized as a unique public and recurring scientific symposium of stem cell and cardiovascular bioengineering. The conference in the past 4 years has added translational topics as well as the “bread and butter” of this meeting, which is the convergences of stem cell biology bioengineering, molecular cardiovascular research, and fabrication of functional myocardium. The conference topics started with tissue engineering, iPS cells, cardiac development, and in the past 2 years has grown to include exosome, microRNAs, mitochondria, cardiac gene and cardiac cell therapy. The attendance of this conference has climbed and, in 2019, the symposium was held at the University of Sydney, Australia. There were nearly 200 attendees from Australia, New Zealand, China, Japan, Europe, and America. In past years, the conference was held in March. The conference was planned for 2020 at the University of Göttingen, but the meeting was cancelled due to COVID-19. Fortunately, we are able to reschedule the meeting for 2021. The planned agenda represents an ambitious, fast-paced meeting with multiple sessions over 2 days including the Keynote lecture. Young cardiovascular scientists will be highlighted through invited talks at each session. Organizers of this meeting are Drs. Wolfram-Hubertus Zimmermann (Göttingen), Jianyi (Jay) Zhang (UAB), Timothy Kamp (UW-Madison), Malte Tiburcy (Göttingen), Laura Zelarayan (Göttingen), Susanne Lutz (Göttingen), Norman Liaw (Göttingen), Patapia Zafeiriou (Göttingen), and Rabea Hinkel (Göttingen). The proposal request of $10,000 constitutes approximately 20% of the total meeting budget, and as we have done over the last several years, support from this application will be used towards the cost of trainee travel, minority travel awards, new investigator travel, and support for videotaping all sessions that will be assessable to the public (Click here to view 2019 CVBE Symposium videos).

项目总结/摘要 这是将于2021年10月11日举行的心血管生物工程2021（CVBE 2021）研讨会的新应用程序。 德国哥廷根大学校园。这将是研讨会的第六周年。的 拟议中的CVBE研讨会的独特之处在于它将心血管领域的顶级研究人员 生物工程领域的受训人员人数不足。培训对象为研究生和博士后 心血管科学和生物医学工程的研究员。研讨会将提供一个论坛， 学员和初级研究人员介绍他们在基因编辑，诱导多能干细胞， 以及心力衰竭背景下的心脏干细胞以及心血管生物工程的一般主题。这 会议源于NHLBI祖细胞生物学联盟（PCBC）的倡议， 最初PCBC心血管研究人员和他们的学员以及特邀演讲者一起参加。2016年作为 PCBC被NHLBI祖细胞翻译联盟（PCTC）所取代，会议发展成为一个公众会议。 研讨会，广泛参与PCBC研究人员以及其他人在心血管生物工程。 多年来，该会议产生了会议记录和立场文件，1-5现在被认为是 一个独特的公共和经常性的干细胞和心血管生物工程科学研讨会。的 过去4年的会议增加了翻译主题以及本次会议的“面包和黄油”， 它是干细胞生物学、生物工程学、分子心血管研究和 功能性心肌的制造。会议主题从组织工程，iPS细胞，心脏 在过去的2年中，已经发展到包括外泌体，microRNA，线粒体，心脏基因 和心脏细胞疗法。本次会议的出席人数不断攀升，2019年， 在澳大利亚悉尼大学。有近200名来自澳大利亚，新西兰，中国， 日本，欧洲，美国。往年，大会都在3月举行。会议计划于 2020年在哥廷根大学举行，但会议因COVID-19而取消。幸运的是，我们能够 把会议改到2021年计划的议程代表了一个雄心勃勃的，快节奏的会议， 两天多场会议，包括主题演讲。年轻的心血管科学家将受到重视 在每一届会议上，通过特邀演讲。本次会议的组织者是Wolfram-Hubertus Zimmermann博士 （哥廷根），Jianyi（Jay）Zhang（UAB），Timothy Kamp（UW-Madison），Malte Tiburcy（哥廷根），Laura Zelarayan（哥廷根），Susanne Lutz（哥廷根），Norman Liaw（哥廷根），Patapia Zafeiriou（哥廷根），and Rabea Hinkel（哥廷根）。10，000美元的提案请求约占会议总额的20% 预算，正如我们在过去几年所做的那样，这项应用程序的支持将用于 受训人员差旅费、少数族裔差旅奖、新调查员差旅费和所有会议录像支助费 公众可参与评估（点击此处查看2019 CVBE研讨会视频）。